Decitabine improves patient outcomes in myelodysplastic syndromes : Results of a phase III randomized study (pages 1794–1803)
Hagop Kantarjian, Jean-Pierre J. Issa, Craig S. Rosenfeld, John M. Bennett, Maher Albitar, John DiPersio, Virginia Klimek, James Slack, Carlos de Castro, Farhad Ravandi, Richard Helmer III, Lanlan Shen, Stephen D. Nimer, Richard Leavitt, Azra Raza and Hussain Saba
Version of Record online: 13 MAR 2006 | DOI: 10.1002/cncr.21792
In a randomized Phase III trial, decitabine was found to be clinically effective in the treatment of patients with myelodysplastic syndromes, with demonstrated durable responses and an improved time to acute myelogenous leukemia transformation or death. Decitabine treatment also was associated with increased transfusion independence, improved cytogenetics, and a better quality of life.
See also pages 1650-2 and pages 1744-50.